Vir Biotechnology announces plans for a public share offering

what happened

Biopharmaceutical company Vir Biotechnology, Inc. said it intends to carry out an underwritten public offering of its common stock. According to TradingView, every share in the proposed deal will be issued by Vir itself. The underwriters also received a 30-day option to buy up to 15% more shares than the base offering, at the offering price minus underwriting discounts and commissions.

Leerink Partners, Morgan Stanley and Evercore ISI are acting as bookrunners, with Raymond James serving as co-manager. The registration statement was filed with the SEC on November 12, 2026, and became automatically effective upon filing. The company stresses that the deal depends on market and other conditions, and gives no assurance that it will be completed or on what size or terms.

why it matters

If the offering goes ahead at the proposed size, more shares would enter circulation, which could dilute existing shareholders. Final details will become clearer once the preliminary prospectus supplement is filed. The story concerns a single company, but it shows that biotech issuers are still raising capital in public markets.

tags

instruments

on polymarket